Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus

References

• Lee WM. Hepatitis B virus infection. N. Engl. J. Med.337, 1733–1745 (1997).
   PubMed Web of Science ®Google Scholar
• Ganem D, Prince AM. Hepatitis B virus infection – natural history and clinical consequences. N. Engl. J. Med.350, 1118–1129 (2004).
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology45, 507–539 (2007).
   PubMed Web of Science ®Google Scholar
• Dienstag JL. Hepatitis B virus infection. N. Engl. J. Med.359, 1486–1500 (2008).
   PubMed Web of Science ®Google Scholar
• Blumberg BS, Alter HJ, Visnich S. A “new” antigen in leukemia sera. JAMA191, 541–546 (1965).
   PubMed Web of Science ®Google Scholar
• Wang FS. Clinical immune characterization of hepatitis B virus infection and implications for immune intervention: progress and challenges. Hepatol. Res.37(Suppl. 3), S339–S346 (2007).
   Google Scholar
• Chang JJ, Lewin SR. Immunopathogenesis of hepatitis B virus infection. Immunol. Cell Biol.85, 16–23 (2007).
   PubMed Web of Science ®Google Scholar
• Tan AT, Koh S, Goh V, Bertoletti A. Understanding the immunopathogenesis of chronic hepatitis B virus: an Asian prospective. J. Gastroenterol. Hepatol.23, 833–843 (2008).
   PubMed Web of Science ®Google Scholar
• Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol.5, 215–229 (2005).
   PubMed Web of Science ®Google Scholar
• Jung MC, Pape GR. Immunology of hepatitis B infection. Lancet Infect. Dis.2, 43–50 (2002).
   PubMed Web of Science ®Google Scholar
• Lee WM. Acute liver failure. N. Engl. J. Med.329, 1862–1872 (1993).
   PubMed Web of Science ®Google Scholar
• Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect. Dis.2, 479–486 (2002).
   PubMed Web of Science ®Google Scholar
• Murray JM, Wieland SF, Purcell RH, Chisari FV. Dynamics of hepatitis B virus clearance in chimpanzees. Proc. Natl Acad. Sci. USA102, 17780–17785 (2005).
   PubMed Web of Science ®Google Scholar
• Guidotti LG, Rochford R, Chung J et al. Viral clearance without destruction of infected cells during acute HBV infection. Science284, 825–829 (1999).
   PubMed Web of Science ®Google Scholar
• Webster GJ, Reignat S, Maini MK et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology32, 1117–1124 (2000).
   PubMed Web of Science ®Google Scholar
• Fisicaro P, Valdatta C, Boni C et al. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut58(7), 974–982 (2009).
   PubMed Web of Science ®Google Scholar
• Szabo G, Mandrekar P, Dolganiuc A. Innate immune response and hepatic inflammation. Semin. Liver Dis.27, 339–350 (2007).
   PubMed Web of Science ®Google Scholar
• Boehme KW, Compton T. Innate sensing of viruses by Toll-like receptors. J. Virol.78, 7867–7873 (2004).
   PubMed Web of Science ®Google Scholar
• Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc. Natl Acad. Sci. USA101, 6669–6674 (2004).
   PubMed Web of Science ®Google Scholar
• Wieland SF, Guidotti LG, Chisari FV. Intrahepatic induction of α/β interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J. Virol.74, 4165–4173 (2000).
   PubMed Web of Science ®Google Scholar
• Wu J, Meng Z, Jiang M et al. Hepatitis B virus suppresses Toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology49, 1132–1140 (2009).
   PubMed Web of Science ®Google Scholar
• Isogawa M, Robek MD, Furuichi Y, Chisari FV. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J. Virol.79, 7269–7272 (2005).
   PubMed Web of Science ®Google Scholar
• Wu J, Lu M, Meng Z et al. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology46, 1769–1778 (2007).
   PubMed Web of Science ®Google Scholar
• Guo H, Jiang D, Ma D et al. Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J. Virol.83, 847–858 (2009).
   PubMed Web of Science ®Google Scholar
• Visvanathan K, Skinner NA, Thompson AJ et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology45, 102–110 (2007).
   PubMed Web of Science ®Google Scholar
• McClary H, Koch R, Chisari FV, Guidotti LG. Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J. Virol.74, 2255–2264 (2000).
   PubMed Web of Science ®Google Scholar
• Pasquetto V, Wieland SF, Uprichard SL, Tripodi M, Chisari FV. Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures. J. Virol.76, 5646–5653 (2002).
   PubMed Web of Science ®Google Scholar
• Guidotti LG, Ishikawa T, Hobbs MV et al. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity4, 25–36 (1996).
   PubMed Web of Science ®Google Scholar
• Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology43, S54–S62 (2006).
   PubMed Web of Science ®Google Scholar
• Karre K. Natural killer cell recognition of missing self. Nat. Immunol.9, 477–480 (2008).
   PubMed Web of Science ®Google Scholar
• Kakimi K, Guidotti LG, Koezuka Y, Chisari FV. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J. Exp. Med.192, 921–930 (2000).
   PubMed Web of Science ®Google Scholar
• Kakimi K, Lane TE, Wieland S et al. Blocking chemokine responsive to γ-2/interferon (IFN)-γ inducible protein and monokine induced by IFN-γ activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J. Exp. Med.194, 1755–1766 (2001).
   PubMed Web of Science ®Google Scholar
• Kimura K, Kakimi K, Wieland S, Guidotti LG, Chisari FV. Activated intrahepatic antigen-presenting cells inhibit hepatitis B virus replication in the liver of transgenic mice. J. Immunol.169, 5188–5195 (2002).
   PubMed Web of Science ®Google Scholar
• Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol.23, 275–306 (2005).
   PubMed Web of Science ®Google Scholar
• Kingham TP, Chaudhry UI, Plitas G et al. Murine liver plasmacytoid dendritic cells become potent immunostimulatory cells after Flt-3 ligand expansion. Hepatology45, 445–454 (2007).
   PubMed Web of Science ®Google Scholar
• Duan XZ, Zhuang H, Wang M et al. Decreased numbers and impaired function of circulating dendritic cell subsets in patients with chronic hepatitis B infection (R2). J. Gastroenterol. Hepatol.20, 234–242 (2005).
   PubMed Web of Science ®Google Scholar
• Ulsenheimer A, Gerlach JT, Jung MC et al. Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection. Hepatology41, 643–651 (2005).
   PubMed Web of Science ®Google Scholar
• Penna A, Artini M, Cavalli A et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. J. Clin. Invest.98, 1185–1194 (1996).
   PubMed Web of Science ®Google Scholar
• Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu. Rev. Immunol.27, 485–517 (2009).
   PubMed Web of Science ®Google Scholar
• Thimme R, Wieland S, Steiger C et al. CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J. Virol.77, 68–76 (2003).
   PubMed Web of Science ®Google Scholar
• Boettler T, Panther E, Bengsch B et al. Expression of the interleukin-7 receptor a chain (CD127) on virus-specific CD8+ T cells identifies functionally and phenotypically defined memory T cells during acute resolving hepatitis B virus infection. J. Virol.80, 3532–3540 (2006).
   PubMed Web of Science ®Google Scholar
• Urbani S, Boni C, Missale G et al. Virus-specific CD8+ lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C. J. Virol.76, 12423–12434 (2002).
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection. J. Virol.78, 5535–5545 (2004).
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang JY, Wherry EJ et al. Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. Gastroenterology134, 1938–1949 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang Z, Jin B, Zhang JY et al. Dynamic decrease in PD-1 expression correlates with HBV-specific memory CD8 T-cell development in acute self-limited hepatitis B patients. J. Hepatol.50, 1163–1173 (2009).
   PubMed Web of Science ®Google Scholar
• Isogawa M, Furuichi Y, Chisari FV. Oscillating CD8+ T cell effector functions after antigen recognition in the liver. Immunity23, 53–63 (2005).
   PubMed Web of Science ®Google Scholar
• Maier H, Isogawa M, Freeman GJ, Chisari FV. PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J. Immunol.178, 2714–2720 (2007).
   PubMed Web of Science ®Google Scholar
• Zerbini A, Pilli M, Boni C et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology134, 1470–1481 (2008).
   PubMed Web of Science ®Google Scholar
• Oliviero B, Varchetta S, Paudice E et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology137(3), 1151–1160 (2009).
   PubMed Web of Science ®Google Scholar
• Dunn C, Brunetto M, Reynolds G et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J. Exp. Med.204, 667–680 (2007).
   PubMed Web of Science ®Google Scholar
• Du J, Liang X, Liu Y et al. Hepatitis B virus core protein inhibits TRAIL-induced apoptosis of hepatocytes by blocking DR5 expression. Cell Death Differ.16, 219–229 (2009).
   PubMed Web of Science ®Google Scholar
• Crispe IN. Hepatic T cells and liver tolerance. Nat. Rev. Immunol.3, 51–62 (2003).
   PubMed Web of Science ®Google Scholar
• Lau AH, Thomson AW. Dendritic cells and immune regulation in the liver. Gut52, 307–314 (2003).
   PubMed Web of Science ®Google Scholar
• Goddard S, Youster J, Morgan E, Adams DH. Interleukin-10 secretion differentiates dendritic cells from human liver and skin. Am. J. Pathol.164, 511–519 (2004).
   PubMed Web of Science ®Google Scholar
• Kunitani H, Shimizu Y, Murata H, Higuchi K, Watanabe A. Phenotypic analysis of circulating and intrahepatic dendritic cell subsets in patients with chronic liver diseases. J. Hepatol.36, 734–741 (2002).
   PubMed Web of Science ®Google Scholar
• Nattermann J, Zimmermann H, Iwan A et al. Hepatitis C virus E2 and CD81 interaction may be associated with altered trafficking of dendritic cells in chronic hepatitis C. Hepatology44, 945–954 (2006).
   PubMed Web of Science ®Google Scholar
• Tanimoto K, Akbar SM, Michitaka K, Horiike N, Onji M. Antigen-presenting cells at the liver tissue in patients with chronic viral liver diseases: CD83-positive mature dendritic cells at the vicinity of focal and confluent necrosis. Hepatol. Res.21, 117–125 (2001).
   PubMed Web of Science ®Google Scholar
• Zhang Z, Chen D, Yao J et al. Increased infiltration of intrahepatic DC subsets closely correlate with viral control and liver injury in immune active pediatric patients with chronic hepatitis B. Clin. Immunol.122, 173–180 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zou ZS, Fu JL et al. Severe dendritic cell perturbation is actively involved in the pathogenesis of acute-on-chronic hepatitis B liver failure. J. Hepatol.49, 396–406 (2008).
   PubMed Web of Science ®Google Scholar
• Maini MK, Boni C, Lee CK et al. The role of virus-specific CD8+ cells in liver damage and viral control during persistent hepatitis B virus infection. J. Exp. Med.191, 1269–1280 (2000).
   PubMed Web of Science ®Google Scholar
• Reignat S, Webster GJ, Brown D et al. Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J. Exp. Med.195, 1089–1101 (2002).
   PubMed Web of Science ®Google Scholar
• Lopes AR, Kellam P, Das A et al. Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J. Clin. Invest.118, 1835–1845 (2008).
   PubMed Web of Science ®Google Scholar
• Boni C, Fisicaro P, Valdatta C et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J. Virol.81, 4215–4225 (2007).
   PubMed Web of Science ®Google Scholar
• Duan XZ, Wang M, Li HW et al. Decreased frequency and function of circulating plasmocytoid dendritic cells (pDC) in hepatitis B virus infected humans. J. Clin. Immunol.24, 637–646 (2004).
   PubMed Web of Science ®Google Scholar
• Zheng BJ, Zhou J, Qu D et al. Selective functional deficit in dendritic cell – T cell interaction is a crucial mechanism in chronic hepatitis B virus infection. J. Viral Hepat.11, 217–224 (2004).
   PubMed Web of Science ®Google Scholar
• van der Molen RG, Sprengers D, Binda RS et al. Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology40, 738–746 (2004).
   PubMed Web of Science ®Google Scholar
• Stoop JN, van der Molen RG, Baan CC et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology41, 771–778 (2005).
   PubMed Web of Science ®Google Scholar
• Franzese O, Kennedy PT, Gehring AJ et al. Modulation of the CD8+-T cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection. J. Virol.79, 3322–3328 (2005).
   PubMed Web of Science ®Google Scholar
• Stoop JN, Woltman AM, Biesta PJ et al. Tumor necrosis factor α inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response. Hepatology46, 699–705(2007).
   PubMed Web of Science ®Google Scholar
• Xu D, Fu J, Jin L et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J. Immunol.177, 739–747 (2006).
   PubMed Web of Science ®Google Scholar
• Barboza L, Salmen S, Goncalves L et al. Antigen-induced regulatory T cells in HBV chronically infected patients. Virology368, 41–49 (2007).
   PubMed Web of Science ®Google Scholar
• Chen L, Zhang Z, Chen W et al. B7-H1 up-regulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B. J. Immunol.178, 6634–6641 (2007).
   PubMed Web of Science ®Google Scholar
• Chang JJ, Thompson AJ, Visvanathan K et al. The phenotype of hepatitis B virus-specific T cells differ in the liver and blood in chronic hepatitis B virus infection. Hepatology46, 1332–1340 (2007).
   PubMed Web of Science ®Google Scholar
• Das A, Hoare M, Davies N et al. Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J. Exp. Med.205, 2111–2124 (2008).
   PubMed Web of Science ®Google Scholar
• Urbani S, Boni C, Amadei B et al. Acute phase HBV-specific T cell responses associated with HBV persistence after HBV/HCV coinfection. Hepatology41, 826–831 (2005).
   PubMed Web of Science ®Google Scholar
• Mackay IR. Autoimmune diseases of the liver, autoimmune hepatitis and primary biliary cirrhosis: unfinished business. Hepatol. Res.37(Suppl. 3), S357–S364 (2007).
   Google Scholar
• Huang J, Kwong J, Sun EC, Liang TJ. Proteasome complex as a potential cellular target of hepatitis B virus X protein. J. Virol.70, 5582–5591 (1996).
   PubMed Web of Science ®Google Scholar
• Bouchard MJ, Schneider RJ. The enigmatic X gene of hepatitis B virus. J. Virol.78, 12725–12734 (2004).
   PubMed Web of Science ®Google Scholar
• Clippinger AJ, Gearhart TL, Bouchard MJ. Hepatitis B virus X protein modulates apoptosis in primary rat hepatocytes by regulating both NF-κB and the mitochondrial permeability transition pore. J. Virol.83, 4718–4731 (2009).
   PubMed Web of Science ®Google Scholar
• Clippinger AJ, Bouchard MJ. Hepatitis B virus HBx protein localizes to mitochondria in primary rat hepatocytes and modulates mitochondrial membrane potential. J. Virol.82, 6798–6811 (2008).
   PubMed Web of Science ®Google Scholar
• Milich D, Liang TJ. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology38, 1075–1086 (2003).
   PubMed Web of Science ®Google Scholar
• Lee BO, Tucker A, Frelin L et al. Interaction of the hepatitis B core antigen and the innate immune system. J. Immunol.182, 6670–6681 (2009).
   PubMed Web of Science ®Google Scholar
• Rossol S, Marinos G, Carucci P et al. Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. J. Clin. Invest.99, 3025–3033 (1997).
   PubMed Web of Science ®Google Scholar
• Untergasser A, Zedler U, Langenkamp A et al. Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection. Hepatology43, 539–547 (2006).
   PubMed Web of Science ®Google Scholar
• Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science270, 1189–1192 (1995).
   PubMed Web of Science ®Google Scholar
• Limmer A, Ohl J, Kurts C et al. Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat. Med.6, 1348–1354 (2000).
   PubMed Web of Science ®Google Scholar
• Bertoletti A, Sette A, Chisari FV et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature369, 407–410 (1994).
   PubMed Web of Science ®Google Scholar
• Bertoletti A, Costanzo A, Chisari FV et al. Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J. Exp. Med.180, 933–943 (1994).
   PubMed Web of Science ®Google Scholar
• Liu HG, Fan ZP, Chen WW et al. A mutant HBs antigen (HBsAg)183–191 epitope elicits specific cytotoxic T lymphocytes in acute hepatitis B patients. Clin. Exp. Immunol.151, 441–447 (2008).
   PubMed Web of Science ®Google Scholar
• Liu HG, Chen WW, Fan ZP et al. The high prevalence of the I27 mutant HBcAg18–27 epitope in Chinese HBV-infected patients and its cross-reactivity with the V27 prototype epitope. Clin. Immunol.125, 337–345 (2007).
   PubMed Web of Science ®Google Scholar
• Leifeld L, Cheng S, Ramakers J et al. Imbalanced intrahepatic expression of interleukin 12, interferon γ, and interleukin 10 in fulminant hepatitis B. Hepatology36, 1001–1008 (2002).
   PubMed Web of Science ®Google Scholar
• Antoniades CG, Berry PA, Davies ET et al. Reduced monocyte HLA-DR expression: a novel biomarker of disease severity and outcome in acetaminophen-induced acute liver failure. Hepatology44, 34–43 (2006).
   PubMed Web of Science ®Google Scholar
• Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J. Biol. Chem.275, 2247–2250 (2000).
   PubMed Web of Science ®Google Scholar
• Jo M, Kim TH, Seol DW et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med.6, 564–567 (2000).
   PubMed Web of Science ®Google Scholar
• Rivero M, Crespo J, Fabrega E et al. Apoptosis mediated by the Fas system in the fulminant hepatitis by hepatitis B virus. J. Viral Hepat.9, 107–113 (2002).
   PubMed Web of Science ®Google Scholar
• Lee JY, Chae DW, Kim SM et al. Expression of FasL and perforin/granzyme B mRNA in chronic hepatitis B virus infection. J. Viral Hepat.11, 130–135 (2004).
   PubMed Web of Science ®Google Scholar
• Ramm GA, Shepherd RW, Hoskins AC et al. Fibrogenesis in pediatric cholestatic liver disease: role of taurocholate and hepatocyte-derived monocyte chemotaxis protein-1 in hepatic stellate cell recruitment. Hepatology49, 533–544 (2009).
   PubMed Web of Science ®Google Scholar
• Fu J, Xu D, Liu Z et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology132, 2328–2339 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang JP, Yan J, Xu J et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J. Hepatol.50, 980–989 (2009).
   PubMed Web of Science ®Google Scholar
• Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat. Clin. Pract. Oncol.4, 424–432 (2007).
   PubMedGoogle Scholar
• Budhu A, Forgues M, Ye QH et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell10, 99–111 (2006).
   PubMed Web of Science ®Google Scholar
• Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology49, S103–S111 (2009).
   PubMed Web of Science ®Google Scholar
• Janssen HL, van Zonneveld M, Senturk H et al. Pegylated interferon α-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet365, 123–129 (2005).
   PubMed Web of Science ®Google Scholar
• Lau GK, Piratvisuth T, Luo KX et al. Peginterferon α-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med.352, 2682–2695 (2005).
   PubMed Web of Science ®Google Scholar
• Marcellin P, Lau GK, Bonino F et al. Peginterferon α-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med.351, 1206–1217 (2004).
   PubMed Web of Science ®Google Scholar
• Boni C, Bertoletti A, Penna A et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J. Clin. Invest.102, 968–975 (1998).
   PubMed Web of Science ®Google Scholar
• Boni C, Penna A, Bertoletti A et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J. Hepatol.39, 595–605 (2003).
   PubMed Web of Science ®Google Scholar
• van der Molen RG, Sprengers D, Biesta PJ, Kusters JG, Janssen HL. Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV. Hepatology44, 907–914 (2006).
   PubMed Web of Science ®Google Scholar
• Stoop JN, van der Molen RG, Kuipers EJ, Kusters JG, Janssen HL. Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B. Virology361, 141–148 (2007).
   PubMed Web of Science ®Google Scholar
• Evans A, Riva A, Cooksley H et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion. Hepatology48, 759–769 (2008).
   PubMed Web of Science ®Google Scholar
• Tang TJ, Kwekkeboom J, Mancham S et al. Intrahepatic CD8+ T-lymphocyte response is important for therapy-induced viral clearance in chronic hepatitis B infection. J. Hepatol.43, 45–52 (2005).
   PubMed Web of Science ®Google Scholar
• Carotenuto P, van Riel D, Artsen A et al. Antiviral treatment with α interferon up-regulates CD14 on liver macrophages and its soluble form in patients with chronic hepatitis B. Antimicrob. Agents Chemother.49, 590–599 (2005).
   PubMed Web of Science ®Google Scholar
• Gregorek H, Dzierzanowska-Fangrat K, Woynarowski M et al. Persistence of HBV-DNA in children with chronic hepatitis B who seroconverted to anti-HBs antibodies after interferon-α therapy: correlation with specific IgG subclass responses to HBsAg. J. Hepatol.42, 486–490 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang H, Chen D et al. Response to interferon-α treatment correlates with recovery of blood plasmacytoid dendritic cells in children with chronic hepatitis B. J. Hepatol.47, 751–759 (2007).
   PubMed Web of Science ®Google Scholar
• Andersson KL, Chung RT. Monitoring during and after antiviral therapy for hepatitis B. Hepatology49, S166–S173 (2009).
   Google Scholar
• Akbar SM, Horiike N, Onji M. Immune therapy including dendritic cell based therapy in chronic hepatitis B virus infection. World J. Gastroenterol.12, 2876–2883 (2006).
   PubMed Web of Science ®Google Scholar
• Shi M, Fu J, Shi F et al. Transfusion of autologous cytokine-induced killer cells inhibits viral replication in patients with chronic hepatitis B virus infection. Clin. Immunol.132, 43–54 (2009).
   PubMed Web of Science ®Google Scholar
• Kuo TK, Hung SP, Chuang CH et al. Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology134, 2111–2121 (2008).
   PubMed Web of Science ®Google Scholar
• Dai LJ, Li HY, Guan LX, Ritchie G, Zhou JX. The therapeutic potential of bone marrow-derived mesenchymal stem cells on hepatic cirrhosis. Stem Cell Res.2, 16–25 (2009).
   PubMed Web of Science ®Google Scholar
• Kharaziha P, Hellstrom PM, Noorinayer B et al. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a Phase I–II clinical trial. Eur. J. Gastroenterol. Hepatol.21(10), 1199–1205 (2009).
   PubMed Web of Science ®Google Scholar
• Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M et al. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch. Iran Med.10, 459–466 (2007).
   PubMed Web of Science ®Google Scholar
• Wang FS, Zhang JY. Bringing the antiviral therapy home for chronic hepatitis B patients: host immunity influences the efficacy and disease prognosis. Zhonghua Gan Zang Bing Za Zhi17, 164–166 (2009).
   PubMedGoogle Scholar
• Liaw YF. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir. Ther.11, 669–679 (2006).
   PubMed Web of Science ®Google Scholar
• Lu M, Menne S, Yang D, Xu Y, Roggendorf M. Immunomodulation as an option for the treatment of chronic hepatitis B virus infection: preclinical studies in the woodchuck model. Expert. Opin. Investig. Drugs16, 787–801(2007).
   PubMed Web of Science ®Google Scholar